(Q38099191)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588303%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

title

Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588303%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588303%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

J C Kalvass

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588303%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

D L Bourdet

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588303%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

B Feng

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588303%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

S-M Huang

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588303%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

X Liu

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588303%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Q R Smith

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588303%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

L K Zhang

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588303%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

M J Zamek-Gliszczynski

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588303%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

International Transporter Consortium

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588303%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

language of work or name

English

0 references

publication date

14 February 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588303%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

28 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588303%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

volume

94

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588303%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588303%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

80-94

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588303%20AND%20SRC:MED&resulttype=core&format=json

Membrane transporters in drug development

28 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Drug interactions at the blood-brain barrier: fact or fantasy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Choroid plexus transport: gene deletion studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Mrp4 confers resistance to topotecan and protects the brain from chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Full efficacy with no CNS side-effects: unachievable panacea or reality? DMPK considerations in design of drugs with limited brain penetration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efflux at the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentratio

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Relationship between drug/metabolite exposure and impairment of excretory transport function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Multidrug resistance-associated proteins: expression and function in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Multidrug resistance protein 4 protects bone marrow, thymus, spleen, and intestine from nucleotide analogue-induced damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Pharmacokinetic role of L-type amino acid transporters LAT1 and LAT2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Molecular biology of nucleoside transporters and their distributions and functions in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Biodistribution and uptake of 3'-deoxy-3'-fluorothymidine in ENT1-knockout mice and in an ENT1-knockdown tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Brain uptake of the drug of abuse γ-hydroxybutyric acid in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Functions of OATP1A and 1B transporters in vivo: insights from mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and efflux of drugs across the blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

In vitro blood-brain barrier models: current and perspective technologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Derivation of blood-brain barrier endothelial cells from human pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Evaluation of the utility of brain slice methods to study brain penetration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Blood-brain barrier P-glycoprotein function in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Blood-brain barrier dysfunction in parkinsonian midbrain in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Intestinal drug transporters: in vivo function and clinical importance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Kinetic analyses for species differences in P-glycoprotein-mediated drug transport.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Comparison of species differences of P-glycoproteins in beagle dog, rhesus monkey, and human using Atpase activity assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

P-glycoprotein-based loperamide-cyclosporine drug interaction at the rat blood-brain barrier: prediction from in vitro studies and extrapolation to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Species differences of inhibitory effects on P-glycoprotein-mediated drug transport.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Use of loperamide as a phenotypic probe of mdr1a status in CF-1 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Increased drug delivery to the brain by P-glycoprotein inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Clinical features and management of poisoning due to antimalarial drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Loperamide and P-glycoprotein inhibition: assessment of the clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

The life and times of ivermectin - a success story

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Ivermectin, 'wonder drug' from Japan: the human use perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Vincristine-induced central neurotoxicity in a collie homozygous for the ABCB1Δ mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

Highlights from the International Transporter Consortium second workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

7 January 2021

Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

7 January 2021

The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

7 January 2021

Effects of anticonvulsants on GLUT1-mediated glucose transport in GLUT1 deficiency syndrome in vitro

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

7 January 2021

Abuse potential of loperamide

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2013.34

7 January 2021

Identifiers

DOI

10.1038/CLPT.2013.34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23588303%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference